ASTRO 2017: QOL Outcomes Among Prostate Cancer Treatment Options

Video
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

This video reviews 4-year quality-of-life results from a prospective, population-based study that looked at prostate cancer patients who selected either active surveillance, radical prostatectomy, or external-beam radiation.

In this video, Ronald C. Chen, MD, MPH, of the University of North Carolina Lineberger Comprehensive Cancer Center in Chapel Hill, discusses a prospective, population-based study examining 4-year quality-of-life results among prostate cancer patients who were treated with either active surveillance, radical prostatectomy, or external-beam radiation.

Chen presented results of the study (abstract LBA-11) at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held September 24–27 in San Diego.

Recent Videos
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Biochemical markers and advanced imaging modalities play a critical role in monitoring patients undergoing RLT therapy for metastatic prostate cancer.
Less lymphocyte depletion with twice-daily radiotherapy warrants further assessment to optimize the synergistic effect of radiotherapy and immunotherapy.
Data support the use of radioligand therapy in combination with androgen receptor pathway inhibitors to optimize prostate cancer outcomes.
Twice-daily thoracic radiotherapy appeared to confer less leukocyte and lymphocyte depletion compared with once-daily radiation in LS-SCLC.
The clinical adoption of twice-daily accelerated radiotherapy has been limited in North America despite improved outcomes, according to Bin Gui, MD.
Related Content
Data from a phase 2 study support further development of sacituzumab tirumotecan plus pembrolizumab in metastatic castration-resistant prostate cancer.

Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC

Russ Conroy
November 2nd 2025
Article

Data from a phase 2 study support further development of sacituzumab tirumotecan plus pembrolizumab in metastatic castration-resistant prostate cancer.

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging

Previous results from the study found improvement in the primary end point of PSA-PFS with apalutamide in recurrent prostate cancer.

Apalutamide/ADT Displays Long-Term Efficacy in Recurrent Prostate Cancer

Jonah Feldman
October 20th 2025
Article

Previous results from the study found improvement in the primary end point of PSA-PFS with apalutamide in recurrent prostate cancer.

1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
April 15th 2025
Podcast

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.

Findings from the ENZARAD trial support adding enzalutamide to androgen deprivation therapy for those with positive lymph nodes.

Enzalutamide Combo Shows No MFS Improvement in Advanced Prostate Cancer

Ryan Scott
October 19th 2025
Article

Findings from the ENZARAD trial support adding enzalutamide to androgen deprivation therapy for those with positive lymph nodes.

At 8 years follow-up, patients with recurrent prostate cancer in the enzalutamide/leuprolide arm had an OS rate of 78.9% vs 69.5% vs leuprolide alone.

Enzalutamide/Leuprolide Regimen Reduces Risk of Death in Prostate Cancer

Tony Berberabe, MPH
October 19th 2025
Article

At 8 years follow-up, patients with recurrent prostate cancer in the enzalutamide/leuprolide arm had an OS rate of 78.9% vs 69.5% vs leuprolide alone.